BACKGROUND: This study was conducted to evaluate the efficacy and toxicity of combination carboplatin and paclitaxel in patients with esophageal cancer. MATERIALS AND METHODS: Thirty-five patients were enrolled. Patients were treated with paclitaxel 200 mg/m(2) intravenously (i.v.) over 3 h and carboplatin i.v. at an AUC of 5 mg/h/ml. Thirty-three patients were assessable for toxicity and objective response. RESULTS: A total of 166 treatment courses were administered with a median of five courses per patient. The objective response rate was 43% [90% confidence interval (CI) 0.3-0.58] by the intention-to-treat analysis. The median response duration was 2.8 months (90% CI 2.1-5.4). The median survival time was 9 months (90% CI 7-13.8) and the 1-year survival rate was 43% (90% CI 0.29-0.57). The major grade 3-4 toxicity observed was neutropenia, occurring in 17 patients (52%). There were no treatment-related deaths. CONCLUSIONS: The combination of carboplatin and paclitaxel is an moderately active and tolerable regimen in advanced esophageal cancer.
BACKGROUND: This study was conducted to evaluate the efficacy and toxicity of combination carboplatin and paclitaxel in patients with esophageal cancer. MATERIALS AND METHODS: Thirty-five patients were enrolled. Patients were treated with paclitaxel 200 mg/m(2) intravenously (i.v.) over 3 h and carboplatin i.v. at an AUC of 5 mg/h/ml. Thirty-three patients were assessable for toxicity and objective response. RESULTS: A total of 166 treatment courses were administered with a median of five courses per patient. The objective response rate was 43% [90% confidence interval (CI) 0.3-0.58] by the intention-to-treat analysis. The median response duration was 2.8 months (90% CI 2.1-5.4). The median survival time was 9 months (90% CI 7-13.8) and the 1-year survival rate was 43% (90% CI 0.29-0.57). The major grade 3-4 toxicity observed was neutropenia, occurring in 17 patients (52%). There were no treatment-related deaths. CONCLUSIONS: The combination of carboplatin and paclitaxel is an moderately active and tolerable regimen in advanced esophageal cancer.
Authors: David J Adelstein; Cristina P Rodriguez; Lisa A Rybicki; Denise I Ives; Thomas W Rice Journal: Invest New Drugs Date: 2011-08-24 Impact factor: 3.850
Authors: Joanne F Rossman; Carla I Falkson; Ronghui Xu; Coenraad F Slabber; Bernard A Mason; Mary F Mulcahy; Al B Benson Journal: Gastrointest Cancer Res Date: 2011-01
Authors: Aminah Jatoi; Shaker R Dakhil; Nathan R Foster; Cynthia Ma; Kendrith M Rowland; Dennis F Moore; Anthony J Jaslowski; Sachdev P Thomas; Mark D Hauge; Patrick J Flynn; Philip J Stella; Steven R Alberts Journal: J Thorac Oncol Date: 2008-05 Impact factor: 15.609
Authors: R C Turkington; C Purcell; C R James; J Millar; E Napier; D Law; R Gallagher; M Morris; R H Wilson; M M Eatock Journal: Invest New Drugs Date: 2013-05-11 Impact factor: 3.850
Authors: Md Sazzad Hassan; Niranjan Awasthi; Jun Li; Margaret A Schwarz; Roderich E Schwarz; Urs von Holzen Journal: PLoS One Date: 2017-02-22 Impact factor: 3.240